Alexion, AstraZeneca Rare Disease's Koselugo (selumetinib), an oral, selective MEK inhibitor, has been approved in Canada for the treatment of adult patients with neurofibromatosis type 1 (NF1) who ...
Automatic tool changer systems are now an important part of many robot and automated solutions, proving key to maintaining flexibility to meet consumer demands. Automated tool changer systems enable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results